Genzyme, a Sanofi Company
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Genzyme, a Sanofi Company sits in the top decile of US sponsors by registered trial count (#154 of 15,742 sponsors by registered trial count).
Genzyme, a Sanofi Company: 196 sponsored US clinical trials, 4 recruiting.
Genzyme, a Sanofi Company sponsors 196 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 159 completed. 65 of these trials are in Phase 3-4 (later-stage) and 114 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Glycogen Storage Disease Type II (GSD-II), with 5 trials.
Top-decile sponsor footprint
Genzyme, a Sanofi Company ranks in the top decile of sponsors by registered trial count (#154 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
159 of 188 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
196 total, page 4 of 4
Study of ILX651 in Patients With Inoperable Locally Advanced or Metastatic Melanoma
NCT00068211
An Investigation Into the Short Term Effect of APOMINE in Patients With Osteoporosis or Low Bone Mass
NCT00078026
A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection
NCT00089947
Efficacy of Seprapack Sinus Dressing Versus No Dressing in the Prevention of Intranasal Adhesions Following Sinus Surgery
NCT00140608
This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.
NCT00059722
Extension Study of Long-term Safety and Efficacy of Myozyme for a Single Patient With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored ERT Studies.
NCT00765414
Extension Study of Long-term Safety and Efficacy of Myozyme in Patients With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored Enzyme Replacement Therapy (ERT) Studies
NCT00763932
A Study of the Safety and Efficacy of rhGAA in Patients With Infantile-onset Pompe Disease
NCT00059280
Study to Compare Once A Day Sevelamer Dosing With Three Times Per Day Sevelamer Dosing
NCT00324376
rhGAA in Patients With Infantile-onset Glycogen Storage Disease-II (Pompe Disease)
NCT00053573
Open-label Trial of Leukine in Active Crohn's Disease
NCT00206700
A Study of the Safety and Pharmacokinetics of rhGAA in Siblings With Glycogen Storage Disease Type II
NCT00051935
A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis
NCT00050778
Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma
NCT00051701
Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme
NCT00837824
Safety/Efficacy of a Vaccine Prepared From Dendritic Cells Combined With Tumor Cells to Treat Advanced Kidney Cancer
NCT00050323
This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.
NCT00047840
A Study of Fabrazyme in Pediatric Patients With Fabry Disease
NCT00074958
Efficacy Study of ZD6474 to Treat Multiple Myeloma Cancer
NCT00047788
Clofarabine in Adult Patients With Advanced Solid Tumors
NCT00125840
Phase II Study of Clofarabine in Pediatric Acute Lymphoblastic Leukemia (ALL)
NCT00042341
Phase II Study of Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia
NCT00044889
Phase II Study of Clofarabine in Pediatric Acute Myelogenous Leukemia (AML) Patients
NCT00042354
This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast Cancer
NCT00034918
A Study of GT160-246 Versus Vancomycin in Patients With Clostridium Difficile-Associated Diarrhea
NCT00034294
Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in Type 1 Gaucher Disease
NCT00364858
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
NCT00046683
A Study of NM-3 Administered Orally in Patients With Advanced Solid Tumors.
NCT00046696
Safety and Efficacy of Recombinant Human Acid Alpha-Glucosidase in the Treatment of Classical Infantile Pompe Disease
NCT00025896
Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients
NCT00146770
Dialysis Clinical Outcomes Revisited (DCOR) Trial
NCT00324571
A Study of the Safety and Efficacy of Fabrazyme (Agalsidase Beta) as Compared to Placebo in Patients With Advanced Fabry Disease
NCT00074984
Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I
NCT00912925
Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome
NCT00017550
An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.
NCT00235300
A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease
NCT00074971
SR-45023A in Treating Patients With Locally Advanced or Metastatic Solid Tumors
NCT00004049
SR-45023A in Treating Patients With Advanced Solid Tumors
NCT00003822
Seprafilm in the Reduction of Incidence of Bowel Obstruction in General Surgery
NCT00130715
A Multicenter Study of the Efficacy of Cerezyme in Testing Skeletal Disease in Patients With Type I Gaucher Disease.
NCT00365131
Phase 2, Double-blind, Randomized, Controlled Multi-center Clinical Trial of the Safety and Efficacy of Transplanted Fetal Porcine Cells in Patients With Parkinson's Disease.
NCT00226460
Chemotherapy in Treating Patients With Advanced or Metastatic Solid Tumors
NCT00003713
Aminopterin in Treating Patients With Refractory Leukemia
NCT00003305
Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis
NCT00043706
Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel
NCT00082134
A Study of Mitoguazone Dihydrochloride in Patients With AIDS-Related Non-Hodgkin's Lymphoma
NCT00002348
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 48 |
| Phase 2 | 66 |
| Phase 3 | 40 |
| Phase 4 | 25 |
Therapeutic Areas
What is open in the Genzyme, a Sanofi Company pipeline
4 recruiting of 196 indexed (2% open); 159 completed (81%).
Phase mix: 65 late (III/IV) vs 114 early (I/II) (early-phase heavy).
Top condition: Glycogen Storage Disease Type II (GSD-II) (5 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Genzyme, a Sanofi Company: open-pipeline peers nationwide
Peers matched on 196 registered trials and 2% open enrollment, not the therapeutic-area sidebar.
Genzyme, a Sanofi Company sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 196 trials (± recruiting share)
- Hospital for Special Surgery, New York · 194 trials · 18% recruiting
- Vertex Pharmaceuticals Incorporated · 191 trials · 10% recruiting
- National Center for Complementary and Integrative Health (NCCIH) · 203 trials · 3% recruiting
- The University of Texas Medical Branch, Galveston · 203 trials · 14% recruiting
Sponsors near 2% open enrollment (± trial volume)
- Cynosure · 2% recruiting · 49 trials
- Carelon Research · 2% recruiting · 50 trials
- Sun Pharmaceutical Industries · 2% recruiting · 48 trials
- Sanofi Pasteur, a Sanofi Company · 2% recruiting · 153 trials
Related
What to do with this Genzyme, a Sanofi Company page
196 registered trials is a research-attention snapshot, not an endorsement of Genzyme, a Sanofi Company or any single study.
- 4 of Genzyme, a Sanofi Company's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Glycogen Storage Disease Type II (GSD-II) is the condition Genzyme, a Sanofi Company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Glycogen Storage Disease Type II (GSD-II) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Genzyme, a Sanofi Company pipeline card: 196 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.